title: MEK inhibition leads to lysosome-mediated Na+/I- symporter protein degradation in human breast cancer cells.
abstract: The Na(+)/I(-) symporter (NIS (SLC5A5)) is a transmembrane glycoprotein that mediates active iodide uptake into thyroid follicular cells. NIS-mediated iodide uptake in thyroid cells is the basis for targeted radionuclide imaging and treatment of differentiated thyroid carcinomas and their metastases. Furthermore, NIS is expressed in many human breast tumors but not in normal non-lactating breast tissue, suggesting that NIS-mediated radionuclide uptake may also allow the imaging and targeted therapy of breast cancer. However, functional cell surface NIS expression is often low in breast cancer, making it important to uncover signaling pathways that modulate NIS expression at multiple levels, from gene transcription to posttranslational processing and cell surface trafficking. In this study, we investigated NIS regulation in breast cancer by MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK) signaling, an important cell signaling pathway involved in oncogenic transformation. We found that MEK inhibition decreased NIS protein levels in all-trans retinoic acid/hydrocortisone-treated MCF-7 cells as well as human breast cancer cells expressing exogenous NIS. The decrease in NIS protein levels by MEK inhibition was not accompanied by a decrease in NIS mRNA or a decrease in NIS mRNA export from the nucleus to the cytoplasm. NIS protein degradation upon MEK inhibition was prevented by lysosome inhibitors but not by proteasome inhibitors. Interestingly, NIS protein level was correlated with MEK/ERK activation in human breast tumors from a tissue microarray. Taken together, MEK activation appears to play an important role in maintaining NIS protein stability in human breast cancers.
authors: Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210, USA.
authors: Zhaoxia
authors: Z
authors: Zhang
authors: Sasha
authors: S
authors: Beyer
authors: Sissy M
authors: SM
authors: Jhiang
mesh_terms: D001943:Breast Neoplasms / Q000378:metabolism*; D002070:Butadienes / Q000494:pharmacology; D045744:Cell Line, Tumor; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology; D007454:Iodides / Q000378:metabolism; D008247:Lysosomes / Q000378:metabolism; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors*; D009570:Nitriles / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D059748:Proteolysis; D012333:RNA, Messenger / Q000378:metabolism; D027981:Symporters / Q000235:genetics / Q000378:metabolism*; D014212:Tretinoin / Q000494:pharmacology; D000099209:Sodium-Iodide Symporters
chemical_list: D002070:Butadienes; D006854:Hydrocortisone; D007454:Iodides; D020929:Mitogen-Activated Protein Kinase Kinases; D009570:Nitriles; D047428:Protein Kinase Inhibitors; D012333:RNA, Messenger; D027981:Symporters; D014212:Tretinoin; D000099209:Sodium-Iodide Symporters; C113580:U 0126
references: J Clin Endocrinol Metab. 2005 Nov;90(11):6131-40
references: 16105966
references: J Clin Invest. 2011 Dec;121(12):4700-11
references: 22105174
references: Clin Cancer Res. 2004 Jul 1;10(13):4294-302
references: 15240514
references: Cancer Sci. 2009 Jun;100(6):1118-27
references: 19514121
references: BMC Cancer. 2007 Jul 25;7:137
references: 17651485
references: Endocr Relat Cancer. 2007 Jun;14(2):421-32
references: 17639055
references: J Biol Chem. 2005 Apr 29;280(17):16651-8
references: 15723837
references: Endocrinology. 2005 Jul;146(7):3059-69
references: 15817668
references: Annu Rev Biochem. 2003;72:395-447
references: 12651740
references: Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8519-24
references: 10890895
references: J Biol Chem. 2012 Jan 27;287(5):3292-300
references: 22157753
references: J Clin Endocrinol Metab. 2004 May;89(5):2344-50
references: 15126562
references: Breast Cancer Res Treat. 2009 May;115(1):205-12
references: 18500672
references: Endocr Relat Cancer. 2006 Mar;13(1):257-69
references: 16601293
references: Mol Cancer Ther. 2007 Jul;6(7):2092-102
references: 17620438
references: J Clin Endocrinol Metab. 2003 Apr;88(4):1880-8
references: 12679487
references: Oncogene. 2007 May 14;26(22):3291-310
references: 17496923
references: Mol Endocrinol. 2006 May;20(5):1121-37
references: 16439463
references: Nat Med. 2000 Aug;6(8):871-8
references: 10932223
references: J Clin Endocrinol Metab. 2006 Jan;91(1):69-78
references: 16234306